Reducing Heart Failure Medicines in Patients Whose Heart Function Has Recovered
Tests cutting back heart medicines in adults whose heart pumping has recovered.
Plain-language title generated from the registry record
Registry title: Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
Key facts
- Where
- Daejeon and Jeonju, South KoreaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure whose heart pumping strength was low at first and has since recovered, and who take at least 3 heart failure medicines. Some will taper their medicine; others will keep taking it.
- Age
- 18 years or older
- Sex
- Women and men can join
- Disease stage
- Heart failure with recovered heart function: first echocardiogram ejection fraction less than 40%, follow-up ejection fraction over 50%, and LVEDD index in the normal range.
- Earlier treatment
- Must be taking more than 3 heart failure medicines (RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor).
- Biomarker or test result
- NTproBNP below a limit that depends on kidney function (eGFR): ≥60 less than 440; 45-59 less than 980; 30-44 less than 1220; below 30 less than 5300. People on haemodialysis have no NTproBNP limit.
Main reasons for not taking part
- Under age 18
- Blood pressure not controlled (over 150/90)
- Coronary revascularization within the last 6 months
- Significant valve disease
- Arrhythmia that needs rate control
Read by machine on 12 November 2026.
Where in South Korea
- Chungnam National University HospitalDaejeon, South KoreaContact: Yujin YangTaking people
- jeonbuk National University HospitalJeonju, South KoreaContact: Jiyeonn LeeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chungnam National University Hospital
- Trial code
- NCT06724653
- Record updated
- 27 March 2026
- Original description
Study start date is on Nov 27th 2024.Read full original descriptionShow less
Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
Study start date is on Nov 27th 2024.
A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
Inclusion: initial echocardiogram ejection fraction less than 40%; follow up echocardiogram ejection fraction over 50% and LVEDD index normal range; NTprobnp criteria; eGFR ≥60 ; less 440; eGFR 45-59: less 980; eGFR 30-44; less 1220; eGFR < 30 : less 5300; in HD; no criteria for NTproBNP; on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor).
Exclusion: significant valve disease; arrhythmia requiring rate control; under age 18 year; uncontrolled BP ( over 150/90); coronary revascularization within 6 months; CKD with albuminuria ( over 30mg/g); Pregnancy.